Maryland's Tobacco Resource Center - Linking Professionals to Best Practices

Chantix Linked to Increased Risk of Heart Attack, Study Finds

July
2011

According to a recent study published in the Canadian Medical Association Journal, the smoking cessation drug Chantix® (generically known as “Varenicline”) may significantly increase the risk of heart attack among middle-aged smokers with no history of heart disease. Specifically, across the 14 clinical trials—involving 8,200 participants—reviewed in the study, the risk for cardiac events requiring hospitalization was found to be 72% higher among smokers who took Chantix in comparison to smokers who did not take the drug (and were, instead, given a placebo). The Food and Drug Administration (FDA) has requested that Pfizer, the company responsible for Chantix®, conduct additional analyses on the drug’s safety.